Literature DB >> 20722500

Analysis of CD14 expression levels in putative mesenchymal progenitor cells isolated from equine bone marrow.

Catherine H Hackett1, Maria Julia B F Flaminio, Lisa A Fortier.   

Abstract

A long-term goal of mesenchymal progenitor cell (MPC) research is to identify cell-surface markers to facilitate MPC isolation. One reported MPC feature in humans and other species is lack of CD14 (lipopolysaccharide receptor) expression. The aim of this study was to evaluate CD14 as an MPC sorting marker. Our hypothesis was that cells negatively selected by CD14 expression would enrich MPC colony formation compared with unsorted and CD14-positive fractions. After validation of reagents, bone marrow aspirate was obtained from 12 horses. Fresh and cultured cells were analyzed by flow cytometry and reverse transcription and quantitative polymerase chain reaction to assess dynamic changes in phenotype. In fresh samples, cells did not consistently express protein markers used for lineage classification. Short-term (2-day) culture allowed distinction between hematopoietic and nonhematopoietic populations. Magnetic activated cell sorting was performed on cells from 6 horses to separate adherent CD14(+) from CD14(-) cells. MPC colony formation was assessed at 7 days. Cells positively selected for CD14 expression were significantly more likely to form MPC colonies than both unsorted and negatively selected cells (P ≤ 0.005). MPCs from all fractions maintained low levels of CD14 expression long term, and upregulated CD14 gene and protein expression when stimulated with lipopolysaccharide. The equine CD14 molecule was trypsin-labile, offering a plausible explanation for the discrepancy with MPC phenotypes reported in other species. By definition, MPCs are considered nonhematopoietic because they lack expression of molecules such as CD14. Our results challenge this assumption, as equine MPCs appear to represent a descendant of a CD14-positive cell.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20722500      PMCID: PMC3128771          DOI: 10.1089/scd.2010.0175

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  21 in total

1.  Cardiomyogenic potential of mesenchymal progenitors derived from human circulating CD14+ monocytes.

Authors:  Hiroaki Kodama; Takafumi Inoue; Ryuichi Watanabe; Hidekata Yasuoka; Yutaka Kawakami; Satoshi Ogawa; Yasuo Ikeda; Katsuhiko Mikoshiba; Masataka Kuwana
Journal:  Stem Cells Dev       Date:  2005-12       Impact factor: 3.272

2.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

3.  Characterisation and developmental potential of ovine bone marrow derived mesenchymal stem cells.

Authors:  Rosa C McCarty; Stan Gronthos; Andrew C Zannettino; Bruce K Foster; Cory J Xian
Journal:  J Cell Physiol       Date:  2009-05       Impact factor: 6.384

4.  Monoclonal antibodies to equine CD14.

Authors:  Esther Kabithe; Julie Hillegas; Tracy Stokol; James Moore; Bettina Wagner
Journal:  Vet Immunol Immunopathol       Date:  2010-07-31       Impact factor: 2.046

5.  Peripheral blood lymphocyte subpopulations and immunoglobulin concentrations in healthy foals and foals with Rhodococcus equi pneumonia.

Authors:  M J Flaminio; B R Rush; W Shuman
Journal:  J Vet Intern Med       Date:  1999 May-Jun       Impact factor: 3.333

Review 6.  Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays.

Authors:  S A Bustin
Journal:  J Mol Endocrinol       Date:  2000-10       Impact factor: 5.098

7.  Isolation of human mesenchymal stem cells from third-trimester amniotic fluid.

Authors:  Qi You; Liying Cai; Jianhua Zheng; Xiaojing Tong; Dan Zhang; Yuanlong Zhang
Journal:  Int J Gynaecol Obstet       Date:  2008-08-29       Impact factor: 3.561

8.  Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation.

Authors:  Masataka Kuwana; Yuka Okazaki; Hiroaki Kodama; Keisuke Izumi; Hidekata Yasuoka; Yoko Ogawa; Yutaka Kawakami; Yasuo Ikeda
Journal:  J Leukoc Biol       Date:  2003-07-22       Impact factor: 4.962

9.  Programmable cells of monocytic origin (PCMO): a source of peripheral blood stem cells that generate collagen type II-producing chondrocytes.

Authors:  Thomas Pufe; Wolf Petersen; Fred Fändrich; Deike Varoga; Christoph J Wruck; Rolf Mentlein; Andreas Helfenstein; Daniela Hoseas; Stefanie Dressel; Bernhard Tillmann; Maren Ruhnke
Journal:  J Orthop Res       Date:  2008-03       Impact factor: 3.494

10.  Isolation and characterization of mouse mesenchymal stem cells.

Authors:  J H Sung; H-M Yang; J B Park; G-S Choi; J-W Joh; C H Kwon; J M Chun; S-K Lee; S-J Kim
Journal:  Transplant Proc       Date:  2008-10       Impact factor: 1.066

View more
  9 in total

1.  Comparison of gene-specific DNA methylation patterns in equine induced pluripotent stem cell lines with cells derived from equine adult and fetal tissues.

Authors:  Catherine H Hackett; Line Greve; Kira D Novakofski; Lisa A Fortier
Journal:  Stem Cells Dev       Date:  2011-11-21       Impact factor: 3.272

2.  Comparison of bone marrow aspiration at the sternum and the tuber coxae in middle-aged horses.

Authors:  Uta Delling; Katrin Lindner; Iris Ribitsch; Henriette Jülke; Walter Brehm
Journal:  Can J Vet Res       Date:  2012-01       Impact factor: 1.310

3.  Comparison of the Chondrogenic Potential of Mesenchymal Stem Cells Derived from Bone Marrow and Umbilical Cord Blood Intended for Cartilage Tissue Engineering.

Authors:  Romain Contentin; Magali Demoor; Miranda Concari; Mélanie Desancé; Fabrice Audigié; Thomas Branly; Philippe Galéra
Journal:  Stem Cell Rev Rep       Date:  2020-02       Impact factor: 5.739

4.  Chondrogenic Differentiation of Defined Equine Mesenchymal Stem Cells Derived from Umbilical Cord Blood for Use in Cartilage Repair Therapy.

Authors:  Mélanie Desancé; Romain Contentin; Lélia Bertoni; Tangni Gomez-Leduc; Thomas Branly; Sandrine Jacquet; Jean-Marc Betsch; Agnès Batho; Florence Legendre; Fabrice Audigié; Philippe Galéra; Magali Demoor
Journal:  Int J Mol Sci       Date:  2018-02-10       Impact factor: 5.923

5.  Isolation and characterization of human gingiva-derived mesenchymal stem cells using limiting dilution method.

Authors:  Lingqian Du; Pishan Yang; Shaohua Ge
Journal:  J Dent Sci       Date:  2016-05-06       Impact factor: 2.080

6.  CD14 is a unique membrane marker of porcine spermatogonial stem cells, regulating their differentiation.

Authors:  Hyun-Jung Park; Won-Young Lee; Chankyu Park; Kwonho Hong; Hyuk Song
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

7.  Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture.

Authors:  A Hagen; H Lehmann; S Aurich; N Bauer; M Melzer; J Moellerberndt; V Patané; C L Schnabel; J Burk
Journal:  Front Bioeng Biotechnol       Date:  2021-01-21

8.  Comparison of Antibacterial and Immunological Properties of Mesenchymal Stem/Stromal Cells from Equine Bone Marrow, Endometrium, and Adipose Tissue.

Authors:  Yennifer Cortés-Araya; Karin Amilon; Burgunde Elisabeth Rink; Georgina Black; Zofia Lisowski; Francesc Xavier Donadeu; Cristina L Esteves
Journal:  Stem Cells Dev       Date:  2018-09-06       Impact factor: 3.272

9.  Distal-Less Homeobox 5 Is a Therapeutic Target for Attenuating Hypertrophy and Apoptosis of Mesenchymal Progenitor Cells.

Authors:  John Twomey-Kozak; Salomi Desai; Wenguang Liu; Neill Y Li; Nicholas Lemme; Qian Chen; Brett D Owens; Chathuraka T Jayasuriya
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.